Home›Oncology› Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancer
Olaparib, rucaparib, and niraparib significantly improve progression-free survival across age groups in advanced ovarian cancerPARP Inhibitors Show Improved Survival for Advanced Ovarian Cancer
Frontiers in MedicinePublished July 9, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that olaparib, rucaparib, and niraparib improve progression-free survival in both younger and older ovarian cancer patients.
This network meta-analysis evaluates the efficacy and safety of various PARP inhibitors, including olaparib, rucaparib, niraparib, senaparib, and veliparib, in patients with advanced ovarian cancer. The study specifically examines progression-free survival (PFS) across different age demographics, including a subset of older patients aged 65 years or more.
For younger patients, olaparib (HR 0.32; 95% CI, 0.19 to 0.54), rucaparib (HR 0.33; 95% CI, 0.16 to 0.69), and niraparib (HR 0.53; 95% CI, 0.38 to 0.74) showed significant improvements in PFS compared to placebo or chemotherapy. In patients aged 65 years or more, olaparib (HR 0.44; 95% CI, 0.25 to 0.77), rucaparib (HR 0.43; 95% CI, 0.19 to 0.97), and niraparib (HR 0.56; 95% CI, 0.38 to 0.83) also demonstrated significant PFS improvements compared to placebo or chemotherapy.
Safety data indicate that niraparib was associated with increased odds of treatment-emergent adverse events (OR, 3.80; 95% CI, 1.72 to 8.39). Additionally, olaparib and niraparib were linked to higher risks of grade 3 or higher anemia and other hematologic toxicities. The authors note that substantial heterogeneity was observed across several efficacy networks and most treatment comparisons relied on indirect evidence.
How this fits prior evidence
This meta-analysis addresses a gap in understanding the efficacy of PARP inhibitors specifically within older populations (aged 65 years or more) with advanced ovarian cancer. While previous coverage noted the role of NLRP3 inflammasome as a target for precision immunotherapy and the use of AI models to predict metastasis, this study provides specific evidence on the comparative progression-free survival benefits of olaparib, rucaparib, and niraparib across different age groups.
Researchers analyzed several types of PARP inhibitors, including olaparib, rucaparib, and niraparib. The study looked at how these drugs performed compared to placebo or chemotherapy in adults with advanced ovarian cancer. This included a specific look at older patients aged 65 and over.
The findings show that olaparib, rucaparib, and niraparib all significantly improved progression-free survival for both younger and older patients. Additionally, senaparib and velaparib were associated with improvements in the overall adult population. These results suggest these medications can be effective across different age groups.
Patients should be aware of potential side effects. The study noted that niraparib was linked to a higher risk of adverse events. Furthermore, both niraparib and olaparib were associated with higher risks of severe anemia and other blood-related toxicities. Because much of the data comes from indirect comparisons, these results are not definitive for every individual case.
What this means for you:
PARP inhibitors show improved survival in ovarian cancer patients of all ages but may increase risks of anemia.
Common questions
Are these treatments effective for older patients?
Yes, the study found that olaparib, rucaparib, and niraparib significantly improved progression-free survival in patients aged 65 and older compared to placebo or chemotherapy. This suggests these medications may be effective for older adults with advanced ovarian cancer.
What are the potential side effects of these drugs?
Some risks were identified, including higher rates of anemia and other blood-related toxicities with niraparib and olaparib. Additionally, niraparib was associated with increased odds of treatment-emergent adverse events. You should discuss these specific risks with your doctor.
How do these drugs compare to standard chemotherapy?
The study found that olaparib, rucaparib, and niraparib improved progression-free survival compared to chemotherapy or placebo. However, the data notes that chemotherapy was ranked most favorably across many safety outcomes.
BackgroundOlder adults with advanced ovarian cancer (AOC) are underrepresented in randomized clinical trials (RCTs), limiting age-specific evidence on poly(ADP-ribose) polymerase inhibitors (PARPi). This network meta-analysis (NMA) compares PARPi efficacy and safety across age groups.MethodsWe searched PubMed, Embase, and Web of Science until January 20, 2026, for RCTs evaluating PARPi in adults with AOC. Screening and extraction utilized Nested Knowledge. Risk of bias was assessed via RoB 2. A frequentist NMA estimated hazard ratios (HR) and odds ratios (OR) with 95% CIs. Treatment rankings utilized P-scores.ResultsA total of 13 RCTs were included. In younger patients, olaparib (HR, 0.32; 95% CI, 0.19–0.54), rucaparib (HR, 0.33; 95% CI, 0.16–0.69), and niraparib (HR, 0.53; 95% CI, 0.38–0.74) significantly improved progression-free survival (PFS) compared with placebo or chemotherapy. Similar benefits were observed in older patients (≥65 years), with significant PFS improvements for olaparib (HR, 0.44; 95% CI, 0.25–0.77), rucaparib (HR, 0.43; 95% CI, 0.19–0.97), and niraparib (HR, 0.56; 95% CI, 0.38–0.83). In the overall adult population, senaparib, veliparib, and olaparib were associated with significant improvements in PFS. Regarding safety, niraparib was associated with increased odds of treatment-emergent adverse events (OR, 3.80; 95% CI, 1.72–8.39), while both niraparib and olaparib were associated with higher risks of grade ≥3 anaemia and other hematologic toxicities. Placebo or chemotherapy ranked most favourably across most safety outcomes. Substantial heterogeneity was observed across several efficacy networks, and most treatment comparisons relied on indirect evidence.ConclusionsPARP inhibitors improved progression-free survival across age groups, including patients aged ≥65 years. However, treatment was associated with increased hematologic and gastrointestinal toxicities. Further studies should assess geriatric outcomes, long-term safety, and patient-reported outcomes.
